Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BCARU vs ACB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACB Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

ACB Overall Winner 6-Pillar Tally: BCARU 0 – 6 ACB Matrix Metrics: BCARU 1 – 9 ACB

As of Nov 20, 2026, Aurora Cannabis Inc. Common Shares (ACB) is the stronger overall head-to-head candidate over D. Boral ARC Acquisition I Corp. Units (BCARU) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BCARU carries a Unified Composite Score of 46.5/100 (HOLD) at $5.17 (N/M Forward P/E, N/A operating margin), whereas ACB carries 44.2/100 (HOLD) at $4.16 (109.9x Forward P/E, -13.8% operating margin).

  • Composite vs. Pillar Nuance: While BCARU currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. ACB 44.2/100 HOLD), ACB captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (-13.8% vs. N/A operating margin) and revenue trajectory (-8.8% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BCARU vs ACB
BCARU NASDAQ
D. Boral ARC Acquisition I Corp. Units
Blank Checks
$5.17
-25.47% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -1.14β · 659% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
ACB NASDAQ Head-to-Head Winner
Aurora Cannabis Inc. Common Shares
Medicinal Chemicals & Botanical Products
$4.16
-2.35% 1D
Market Cap $280.1M
TTM Revenue $314M
Forward P/E 109.9x
Beta / 30D Vol 1.06β · 88% Vol
Unified Composite Score
44.2 / 100 HOLD
Tech 20.0 Fund 46.0 Flow 61.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.5 · SMA20: $4.63 · SMA50: $4.31

6-Pillar Scorecard Institutional Category Breakdown (BCARU 0 – 6 ACB)

Columns: Metric · BCARU · ACB
1. Valuation Multiples ACB
Forward P/E N/M 109.9x
Trailing P/E N/M 109.9x
PEG Ratio N/M N/M
EV / Revenue N/M 0.8x
2. Growth & Scale ACB
Revenue Growth (YoY) N/A -8.8%
Earnings Growth (YoY) N/A -94.7%
TTM Revenue (USD) N/A $314M
Market Cap N/A $280.1M
3. Profitability & Quality ACB
Gross Margin N/A 44.2%
Operating Margin N/A -13.8%
Net Profit Margin N/A -38.2%
Return on Equity (ROE) N/A -9.4%
4. Balance Sheet & Cash Flow ACB
Cash Generation (TTM) N/A -$25M
Cash Flow Margin N/A -8.1%
Net Cash / Leverage N/A ROE $44M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ACB
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 321.4% (60th %ile)
Put/Call OI Skew N/A 0.25x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat ACB
OpEx & R&D Intensity N/A 58.0% of Rev ($182M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Blank Checks Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BCARU (1) vs ACB (9)
Institutional Metric BCARU ACB Criterion Row Edge
Market Capitalization
Scale
N/A $280.1M Larger Scale ACB
Trailing P/E Ratio
Valuation
N/M 109.9x Lower Multiple ACB
Forward P/E Ratio
Valuation
N/M 109.9x Lower Multiple ACB
Revenue Growth (YoY)
Growth
N/A -8.8% Higher Growth ACB
Operating Margin (TTM)
Profitability
N/A -13.8% Higher Margin ACB
Net Profit Margin
Profitability
N/A -38.2% Higher Margin ACB
Return on Equity (ROE)
Capital Efficiency
N/A -9.4% Higher ROE ACB
52-Week Range Position
Momentum
20% ($3–$14) 42% ($3–$6) Stronger Trend ACB
Beta / 30D Volatility
Risk Regime
-1.14β · 659% Vol 1.06β · 88% Vol Lower Realized Risk ACB
Unified Institutional Score
Composite Signal
46.5 / 100 (HOLD) 44.2 / 100 (HOLD) Higher Composite BCARU
Trailing 12M Revenue (USD)
Operating Scale
N/A $314M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 44.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$25M ($44M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACB +99.66 pp
BCARU: -56.96% · ACB: +42.7%
3M Horizon ACB +43.45 pp
BCARU: -49.76% · ACB: -6.31%
6M Horizon ACB +38.63 pp
BCARU: -51.46% · ACB: -12.83%
1Y Horizon ACB +38.63 pp
BCARU: -51.46% · ACB: -12.83%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCARU vs ACB. Trailing 12-month operating profitability (BCARU N/A vs ACB -13.8%) and valuation multiples (BCARU N/M vs ACB 109.9x Forward P/E) are benchmarked directly in Pillar 4 below.

BCARU ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ACB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$314M
Gross Margin44.2%
Op. Margin-13.8%
ROE / Fwd P/E-9.4% · 109.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BCARU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BCARU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACB CONSOLIDATION
33d in phase · OBV DISTRIBUTION
Current IV 321.4%
IV Percentile 60th %ile
Put/Call OI Skew 0.25x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ACB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BCARU Moat Profile Cyclical / Execution-Driven Positioning
Blank Checks Operator
Competes within the Blank Checks value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ACB Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $280.1M market capitalization and -13.8% operating margin.
OpEx & R&D Reinvestment 58.0% of Rev ($182M)
90D Engineering Disclosures 0 Published

Investor FAQ BCARU vs ACB Key Questions & Quantitative Answers

As of Nov 20, 2026, Aurora Cannabis Inc. Common Shares (ACB) is the stronger overall head-to-head candidate over D. Boral ARC Acquisition I Corp. Units (BCARU) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BCARU carries a Unified Composite Score of 46.5/100 (HOLD) at $5.17 (N/M Forward P/E, N/A operating margin), whereas ACB carries 44.2/100 (HOLD) at $4.16 (109.9x Forward P/E, -13.8% operating margin). Composite vs. Pillar Nuance: While BCARU currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. ACB 44.2/100 HOLD), ACB captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (-13.8% vs. N/A operating margin) and revenue trajectory (-8.8% vs. N/A YoY).

ACB leads the Growth & Scale pillar: BCARU posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ACB at -8.8% YoY revenue growth and -94.7% YoY earnings growth on $314M TTM revenue (44.2% gross margin, -13.8% operating margin). On trailing 12-month operating scale, BCARU generates N/A in USD-normalized revenue versus $314M for ACB. In operating R&D and SG&A reinvestment, BCARU deploys N/A (0 90-day corporate R&D disclosures) versus 58.0% of Rev ($182M) (0 disclosures) for ACB.

ACB screens cheaper on headline valuation multiples. BCARU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ACB trades at 109.9x Forward P/E, 109.9x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-8.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BCARU (N/A ROE) versus ACB (-9.4% ROE) capital efficiency.

In options market volatility and institutional positioning, BCARU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-1.14β · 659% Vol realized risk). By comparison, ACB carries 321.4% implied volatility (60th %ile, Elevated (60th–80th %ile)), a 0.25x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.06β · 88% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.